HIV Mutation N348I and Drug Resistance
Author Information
Author(s): Matthias Götte
Primary Institution: McGill University
Hypothesis
Should connection domain mutations of HIV-1 reverse transcriptase be included in HIV resistance testing?
Conclusion
The N348I mutation in HIV-1 reverse transcriptase is associated with increased resistance to zidovudine and nevirapine.
Supporting Evidence
- N348I is the 9th most prevalent RT-associated mutation among treatment-experienced patients.
- N348I confers a 2-fold increase in AZT resistance compared to wild-type virus.
- N348I is associated with an 8-fold increase in resistance to nevirapine.
Takeaway
Scientists found a common mutation in HIV that makes it harder to treat with certain drugs. This mutation shows up often in people who have been treated before.
Methodology
The study analyzed HIV sequences from a cohort in Canada, comparing treatment-experienced and treatment-naïve individuals.
Limitations
The clinical relevance of connection and RNase H mutations remains unclear.
Participant Demographics
Included treatment-experienced patients (n = 1,009) and treatment-naïve individuals (n = 368).
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website